All the news Showing 10 of 217 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead rocked by phase 3 failure of selonsertib in NASH Fierce BioTech / 13 February 2019 Washington takes 'Netflix' hep C drug pricing further with winner-take-all bidding Fierce Pharma / 29 January 2019 The Economics Of Cures - Gilead At A Turning Point Seeking Alpha / 28 January 2019 UK court dismisses AbbVie's legal challenge against the NHS The Lancet (free registration required) / 25 January 2019 A Big, Fatty Opportunity for Big Pharma Wall Street Journal / 18 January 2019 NHS England’s plan to eliminate Hepatitis C decisively backed by High Court NHS England / 18 January 2019 Merck loses bid to revive $200 million Gilead verdict at U.S. high court Reuters UK / 08 January 2019 Mavyret maker AbbVie slaps NHS England with lawsuit over hepatitis C drug procurement: report FiercePharma / 11 November 2018 Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales? FiercePharma / 29 October 2018 Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection Janssen press release / 05 October 2018 ← Prev12345...22Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Noticeboard Email bulletins News feeds